INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS‐A)
Adalgisa Condoluci(Ente Ospedaliero Cantonale), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Robin Foà(Sapienza University of Rome), Lodovico Terzi di Bergamo(Institute of Oncology Research), Georg Stüssi(Institute of Oncology Research), Julio Delgado(Departament de Salut), Massimo Gentile(Azienda Ospedaliera di Cosenza), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Richard Rosenquist(Karolinska University Hospital), Giorgia Chiodin(University of Southampton), Francesca Romana Mauro(Sapienza University of Rome), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Mattias Mattsson(Uppsala University Hospital), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Manlio Ferrarini(North Shore University Hospital), Carmen Herling(University Hospital Leipzig), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Antonino Neri(University of Milan), Michael Doubek(Central European Institute of Technology), Michele Ghielmini(Institute of Oncology Research), Franco Cavalli(Institute of Social and Preventive Medicine), B. Gerber(University of Zurich), Manuela A. Hoechstetter(Ludwig-Maximilians-Universität München), Jana Kotašková(Central European Institute of Technology), Emili Montserrat(Universitat de Barcelona), Šárka Pospı́šilová(Central European Institute of Technology), Jasmin Bahlo(University Hospital Cologne), Michael Hallek(Integrated Oncology (United States)), Francesco Forconi(University of Leeds), Clara Deambrogi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), William G. Wierda(University of Maryland, Baltimore), Giovanna Cutrona(Ospedale Policlinico San Martino), Emanuele Zucca(Università della Svizzera italiana), Petra Langerbeins(University of Cologne)
Cited by 2
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k